Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 0%
Buy 27%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is a leader in a structurally growing market, supported by global trends such as aging populations and increasing prevalence of obesity. Their recent focus on digital health and strong financials, including a projected revenue growth of 5-7% in FY27, make them an attractive investment opportunity with a positive outlook for future growth and potential for shareholder returns. The company's commitment to sustainability and diversity adds to their overall appeal and aligns with the current societal and market expectations.

Bears say

ResMed is facing several challenges that may negatively impact its financial performance and stock value in the near future, including a gross margin miss and potential contraction in gross margins in the upcoming quarter due to cost inflation and higher freight costs. Additionally, the company's growth in the Americas market has been weaker than expected, and its tax rate has increased. There is also a potential risk for a large acquisition that may not be as value-accretive as expected. While ResMed has made efforts to innovate and expand into digital health, the potential for new products or therapies to disrupt its offerings remains a concern. As a result, a negative outlook can be justified for ResMed's stock, as these fundamental factors may hinder its financial performance and stock price in the future.

ResMed (RMD) has been analyzed by 11 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 27% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Hold based on their latest research and market trends.

According to 11 analysts, ResMed (RMD) has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $240.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $240.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.